A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease

NCT00207662 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

580

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: infliximab or placebo

Sponsor

Centocor, Inc.